To observe the clinical efficacy and safety of dexamethasone injection combined with tranexamic acid injection in the treatment of patients with hyperfibrinolysis caused by bleeding after prostatic hyperplasia.

Patients with hyperfibrinolysis caused by hemorrhage after prostatic hyperplasia were randomly divided into control group and treatment group. The control group was given 1 g·d^-1 tranexamic acid intravenously. On the basis of the control group, the treatment group was given dexamethasone 10 mg, intravenous injection, q12 h. Both groups were treated continuously for 5 days. The clinical efficacy, coagulation factor level, quality of life (QOL) score, international prostate symptom score (IPSS), and safety were compared between the two groups.

In the treatment group, 52 cases were enrolled, 2 cases fell off, and finally 50 cases were included in the statistical analysis. In the control group, 51 cases were enrolled, 1 case fell off, and finally 50 cases were included in the statistical analysis. After treatment, the total effective rates of treatment group and control group were 94.00% (47 cases /50 cases) and 72.00% (36 cases /50 cases), respectively, and the difference was statistically significant (P<0.05). After treatment, the partial thromboplastin time of treatment group and control group were (35.12±4.38) and (49.14±5.61)s; the prothrombin time were (12.78±1.67) and (16.10±1.94) s; D-dimer levels were (350.42±25.90) and (380.90±37.10) μg·L^-1; QOL scores were (1.16±0.37) and (2.26±0.78) points, IPSS were (4.48±1.22) and (16.12±3.67) points, respectively. The differences of above indexes were statistically significant between two groups (all P<0.05). The adverse drug reactions of two groups were mainly abdominal pain, anemia and headache. The incidences of total adverse drug reactions in treatment group and control group were 6.00% and 16.00%, respectively, without statistical significance (P>0.05).

Dexamethasone injection combined with tranatemylic acid injection has a definitive clinical efficacy in the treatment of patients with bleeding induced hyperfibrinolytic hyperplasia after prostatic hyperplasia, which can significantly improve the coagulation function of patients, relieve symptoms, without increasing the incidence of adverse drug reactions.